Biomarker Focus Firalis offers a broad biomarker portfolio for diagnostic, prognostic and theranostic tools (RUO kits and IVD tools) across cardiovascular, inflammatory, autoimmune and neurology areas, presenting multiple cross-sell opportunities to biotech, pharma and clinical labs seeking biomarker-based solutions.

Service Expansion Their biomarker-related CRO services span proteomics, genomics/transcriptomics, flow cytometry, assay development, biobanking, data analytics and regulatory support, enabling partnership to cover end-to-end biomarker discovery and qualification for drug development programs.

Regulatory Readiness Firalis emphasizes regulatory alignment with Health Authorities (FDA/EMA) and maintains quality standards (ISO 9001, ISO 13485, ISO 17025), making them a compelling partner for clients needing compliant biomarker development, validation and qualification workflows.

Strategic Growth Recent funding from Bpifrance under France 2030 and investment in advanced sequencing infrastructure (Illumina NovaSeq X Plus) indicate capacity for scale-up, enabling collaborations on larger biomarker panels and data-intensive projects.

Clinical & Precision Medicine With capabilities in patient stratification and personalized medicine, Firalis can target pharma and biotech sponsors pursuing companion diagnostics, precision therapy trials and patient-tailored treatment strategies, expanding opportunities in clinical development partnerships.